Introduction to the PCSK9 Treatment Market Cardiovascular disease management has been revolutionized by the introduction of PCSK9 inhibitors, a class of biologics that have redefined treatment possibilities for patients with severe hypercholesterolemia. The PCSK9 Treatment Market has experienced remarkable growth since the first approvals in 2015, establishing a new paradigm in the management of Read.